Total Payments
$37,537
2024 Payments
$24.82
Companies
16
Transactions
74
Medicare Patients
1,941
Medicare Billing
$346,936
Payment Breakdown by Category
Research$34,257 (91.3%)
Travel$1,723 (4.6%)
Food & Beverage$1,395 (3.7%)
Education$161.35 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $34,257 | 36 | 91.3% |
| Travel and Lodging | $1,723 | 6 | 4.6% |
| Food and Beverage | $1,395 | 27 | 3.7% |
| Education | $161.35 | 5 | 0.4% |
Payments by Type
Research
$34,257
36 transactions
General
$3,280
38 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $22,839 | 15 | $0 (2020) |
| American Regent | $4,760 | 2 | $0 (2020) |
| Exact Sciences Corporation | $4,073 | 2 | $0 (2023) |
| Novo Nordisk AS | $1,365 | 4 | $0 (2019) |
| SANOFI-AVENTIS U.S. LLC | $1,214 | 4 | $0 (2017) |
| Luitpold Pharmaceuticals Inc | $1,207 | 4 | $0 (2017) |
| AbbVie, Inc. | $749.18 | 7 | $0 (2019) |
| Bayer HealthCare Pharmaceuticals Inc. | $621.59 | 6 | $0 (2017) |
| Novo Nordisk Inc | $161.35 | 5 | $0 (2023) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $145.50 | 4 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24.82 | 1 | Amgen Inc. ($24.82) |
| 2023 | $4,105 | 3 | Exact Sciences Corporation ($4,073) |
| 2022 | $96.81 | 3 | Novo Nordisk Inc ($96.81) |
| 2021 | $61.25 | 3 | Novo Nordisk Inc ($32.27) |
| 2020 | $13,942 | 11 | Regeneron Pharmaceuticals, Inc. ($11,374) |
| 2019 | $6,982 | 25 | Regeneron Pharmaceuticals, Inc. ($2,405) |
| 2018 | $9,216 | 10 | Regeneron Pharmaceuticals, Inc. ($9,059) |
| 2017 | $3,109 | 18 | SANOFI-AVENTIS U.S. LLC ($1,214) |
All Payment Transactions
74 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/07/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $24.82 | General |
| Category: Bone Health | ||||||
| 11/15/2023 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | — | Cash or cash equivalent | $1,073.00 | Research |
| Study: Informed Choice Intervention for Colorectal Cancer Screening - COMPASS • Category: Oncology | ||||||
| 04/26/2023 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 01/11/2023 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | — | Cash or cash equivalent | $3,000.00 | Research |
| Study: Informed Choice Intervention for Colorectal Cancer Screening - COMPASS • Category: Oncology | ||||||
| 11/09/2022 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 11/09/2022 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 03/27/2022 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 04/07/2021 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.79 | General |
| Category: Gastroenterology | ||||||
| 03/31/2021 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 01/11/2021 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.19 | General |
| Category: Gastroenterology | ||||||
| 10/08/2020 | Regeneron Pharmaceuticals, Inc. | PRALUENT (Biological) | — | Cash or cash equivalent | $1,177.06 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECT OF PRALUENT ON NEUROCOGNITIVE FUNCTION IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR WITH NON-FAMILIAL HYPERCHOLESTEROLEMIA AT HIGH AND VERY HIGH CARDIOVASCULAR RISK • Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 08/26/2020 | Regeneron Pharmaceuticals, Inc. | PRALUENT (Biological) | — | Cash or cash equivalent | $5,979.00 | Research |
| Study: LONG TERM SAFETY STUDY OF PRALUENT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR WITH NON-FAMILIAL HYPERCHOLESTEROLEMIA AT HIGH AND VERY HIGH CARDIOVASCULAR RISK AND PREVIOUSLY ENROLLED IN THE NEUROCOGNITIVE FUNCTION TRIAL • Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 08/20/2020 | Lilly USA, LLC | BASAGLAR (Drug), TRULICITY, JARDIANCE | Food and Beverage | In-kind items and services | $20.22 | General |
| Category: Diabetes | ||||||
| 08/06/2020 | Regeneron Pharmaceuticals, Inc. | PRALUENT (Biological) | — | Cash or cash equivalent | $242.10 | Research |
| Study: LONG TERM SAFETY STUDY OF PRALUENT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR WITH NON-FAMILIAL HYPERCHOLESTEROLEMIA AT HIGH AND VERY HIGH CARDIOVASCULAR RISK AND PREVIOUSLY ENROLLED IN THE NEUROCOGNITIVE FUNCTION TRIAL • Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 07/29/2020 | Regeneron Pharmaceuticals, Inc. | PRALUENT (Biological) | — | Cash or cash equivalent | $506.59 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECT OF PRALUENT ON NEUROCOGNITIVE FUNCTION IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR WITH NON-FAMILIAL HYPERCHOLESTEROLEMIA AT HIGH AND VERY HIGH CARDIOVASCULAR RISK • Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 07/29/2020 | Regeneron Pharmaceuticals, Inc. | PRALUENT (Biological) | — | Cash or cash equivalent | $115.54 | Research |
| Study: LONG TERM SAFETY STUDY OF PRALUENT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR WITH NON-FAMILIAL HYPERCHOLESTEROLEMIA AT HIGH AND VERY HIGH CARDIOVASCULAR RISK AND PREVIOUSLY ENROLLED IN THE NEUROCOGNITIVE FUNCTION TRIAL • Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 07/09/2020 | Regeneron Pharmaceuticals, Inc. | PRALUENT (Biological) | — | Cash or cash equivalent | $2,794.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECT OF PRALUENT ON NEUROCOGNITIVE FUNCTION IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR WITH NON-FAMILIAL HYPERCHOLESTEROLEMIA AT HIGH AND VERY HIGH CARDIOVASCULAR RISK • Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 07/07/2020 | Amgen Inc. | Aimovig (Biological), Otezla, Repatha | Food and Beverage | In-kind items and services | $27.73 | General |
| Category: Neuroscience | ||||||
| 05/27/2020 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $19.28 | General |
| Category: CARDIOVASCULAR | ||||||
| 02/12/2020 | American Regent | INJECTAFER (Drug) | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: Heart_FID • Category: Anemia | ||||||
| 01/28/2020 | Regeneron Pharmaceuticals, Inc. | PRALUENT (Biological) | — | Cash or cash equivalent | $560.15 | Research |
| Study: LONG TERM SAFETY STUDY OF PRALUENT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR WITH NON-FAMILIAL HYPERCHOLESTEROLEMIA AT HIGH AND VERY HIGH CARDIOVASCULAR RISK AND PREVIOUSLY ENROLLED IN THE NEUROCOGNITIVE FUNCTION TRIAL • Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 12/12/2019 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $18.93 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/13/2019 | Regeneron Pharmaceuticals, Inc. | PRALUENT (Biological) | — | Cash or cash equivalent | $1,044.86 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk • Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 11/07/2019 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $20.79 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/06/2019 | Regeneron Pharmaceuticals, Inc. | PRALUENT (Biological) | — | Cash or cash equivalent | $811.75 | Research |
| Study: Long Term Safety Study of PRALUENT in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk and Previously Enrolled in the Neurocognitive Function Trial • Category: CARDIOVASCULAR AND METABOLISM | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Long Term Safety Study of PRALUENT in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk and Previously Enrolled in the Neurocognitive Function Trial | Regeneron Pharmaceuticals, Inc. | $9,871 | 6 |
| LONG TERM SAFETY STUDY OF PRALUENT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR WITH NON-FAMILIAL HYPERCHOLESTEROLEMIA AT HIGH AND VERY HIGH CARDIOVASCULAR RISK AND PREVIOUSLY ENROLLED IN THE NEUROCOGNITIVE FUNCTION TRIAL | Regeneron Pharmaceuticals, Inc. | $6,897 | 4 |
| Heart_FID | American Regent | $4,760 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECT OF PRALUENT ON NEUROCOGNITIVE FUNCTION IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR WITH NON-FAMILIAL HYPERCHOLESTEROLEMIA AT HIGH AND VERY HIGH CARDIOVASCULAR RISK | Regeneron Pharmaceuticals, Inc. | $4,478 | 3 |
| Informed Choice Intervention for Colorectal Cancer Screening - COMPASS | Exact Sciences Corporation | $4,073 | 2 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk | Regeneron Pharmaceuticals, Inc. | $1,594 | 2 |
| A 26-Week Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus | SANOFI-AVENTIS U.S. LLC | $1,214 | 4 |
| M16-100 | AbbVie, Inc. | $749.18 | 7 |
| BAY 94 8862 ph 3 conventional in diab nephropathy | Bayer HealthCare Pharmaceuticals Inc. | $621.59 | 6 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 472 | 1,254 | $148,510 | $106,160 |
| 2022 | 6 | 359 | 1,019 | $113,810 | $78,041 |
| 2021 | 6 | 485 | 1,132 | $122,830 | $80,265 |
| 2020 | 10 | 625 | 1,364 | $143,120 | $82,470 |
Total Patients
1,941
Total Services
4,769
Medicare Billing
$346,936
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 164 | 567 | $56,700 | $40,539 | 71.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 165 | 349 | $45,370 | $34,396 | 75.8% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Facility | 2023 | 33 | 220 | $28,600 | $19,125 | 66.9% |
| 99306 | Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Facility | 2023 | 51 | 52 | $10,400 | $7,596 | 73.0% |
| 99305 | Initial nursing facility care with moderate level of medical decision making, per day, if using time, at least 35 minutes | Facility | 2023 | 13 | 16 | $2,720 | $1,627 | 59.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 32 | 36 | $2,900 | $1,574 | 54.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 14 | 14 | $1,820 | $1,303 | 71.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 177 | 618 | $61,780 | $44,741 | 72.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 115 | 180 | $23,400 | $16,753 | 71.6% |
| 99309 | Follow-up nursing facility visit per day, typically 25 minutes | Facility | 2022 | 20 | 167 | $21,710 | $12,096 | 55.7% |
| 99306 | Initial nursing facility visit per day, typically 45 minutes | Facility | 2022 | 13 | 15 | $3,000 | $2,000 | 66.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 16 | 16 | $2,080 | $1,440 | 69.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 18 | 23 | $1,840 | $1,011 | 55.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 202 | 484 | $48,400 | $34,833 | 72.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 103 | 177 | $23,010 | $16,443 | 71.5% |
| 99309 | Subsequent nursing facility visit, typically 25 minutes per day | Facility | 2021 | 30 | 211 | $27,430 | $15,686 | 57.2% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 111 | 220 | $17,600 | $8,995 | 51.1% |
| 99306 | Initial nursing facility visit, typically 45 minutes per day | Facility | 2021 | 16 | 17 | $3,400 | $2,326 | 68.4% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 23 | 23 | $2,990 | $1,982 | 66.3% |
| 99309 | Subsequent nursing facility visit, typically 25 minutes per day | Facility | 2020 | 54 | 366 | $47,580 | $27,684 | 58.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 153 | 308 | $30,800 | $18,585 | 60.3% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 118 | 330 | $26,400 | $12,591 | 47.7% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 94 | 94 | $12,220 | $7,048 | 57.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 65 | 74 | $9,620 | $6,082 | 63.2% |
| 99306 | Initial nursing facility visit, typically 45 minutes per day | Facility | 2020 | 27 | 27 | $5,400 | $3,654 | 67.7% |
About Dr. Eugene Soroka, MD
Dr. Eugene Soroka, MD is a Family Medicine healthcare provider based in Port Hueneme, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1437109683.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eugene Soroka, MD has received a total of $37,537 in payments from pharmaceutical and medical device companies, with $24.82 received in 2024. These payments were reported across 74 transactions from 16 companies. The most common payment nature is "" ($34,257).
As a Medicare-enrolled provider, Soroka has provided services to 1,941 Medicare beneficiaries, totaling 4,769 services with total Medicare billing of $346,936. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Port Hueneme, CA
- Active Since 05/10/2006
- Last Updated 01/14/2008
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1437109683
Products in Payments
- PRALUENT (Biological) $13,780
- PRALUENT ALIROCUMAB INJECTION (Biological) $9,059
- INJECTAFER (Drug) $5,967
- Cologuard Collection Kit (Device) $4,073
- NO PRODUCT DISCUSSED (Drug) $1,214
- Androgel (Drug) $749.18
- Non-Covered $621.59
- XIFAXAN (Drug) $145.50
- ENTRESTO (Drug) $119.48
- XARELTO (Drug) $104.29
- Aimovig (Biological) $56.11
- FARXIGA (Drug) $31.90
- INVOKAMET (Drug) $26.10
- EVENITY (Biological) $24.82
- BASAGLAR (Drug) $20.22
- Myrbetriq (Drug) $16.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.